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Abstract
Mutations in the skeletal muscle a-actin gene (ACTA1) cause congenital myopathies including nemaline myopathy, actin
aggregate myopathy and rod-core disease. The majority of patients with ACTA1 mutations have severe hypotonia and do
not survive beyond the age of one. A transgenic mouse model was generated expressing an autosomal dominant mutant
(D286G) of ACTA1 (identified in a severe nemaline myopathy patient) fused with EGFP. Nemaline bodies were observed in
multiple skeletal muscles, with serial sections showing these correlated to aggregates of the mutant skeletal muscle a-actin-
EGFP. Isolated extensor digitorum longus and soleus muscles were significantly weaker than wild-type (WT) muscle at 4
weeks of age, coinciding with the peak in structural lesions. These 4 week-old mice were ,30% less active on voluntary
running wheels than WT mice. The a-actin-EGFP protein clearly demonstrated that the transgene was expressed equally in
all myosin heavy chain (MHC) fibre types during the early postnatal period, but subsequently became largely confined to
MHCIIB fibres. Ringbinden fibres, internal nuclei and myofibrillar myopathy pathologies, not typical features in nemaline
myopathy or patients with ACTA1 mutations, were frequently observed. Ringbinden were found in fast fibre predominant
muscles of adult mice and were exclusively MHCIIB-positive fibres. Thus, this mouse model presents a reliable model for the
investigation of the pathobiology of nemaline body formation and muscle weakness and for evaluation of potential
therapeutic interventions. The occurrence of core-like regions, internal nuclei and ringbinden will allow analysis of the
mechanisms underlying these lesions. The occurrence of ringbinden and features of myofibrillar myopathy in this mouse
model of ACTA1 disease suggests that patients with these pathologies and no genetic explanation should be screened for
ACTA1 mutations.
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Introduction
Nemaline myopathy (one of the commonest congenital
myopathies) is a genetic disease of skeletal muscle classified by
muscle weakness and the presence of rod-like accumulations
within the myofibres called nemaline bodies (‘‘nema’’ from the
Greek word meaning thread; [1]). Patients usually present at birth
with hypotonia, and frequently with respiratory insufficiency
requiring mechanical ventilation [2]. In the most severe cases,
death results within the first year of life [2]. However, adult-onset
cases with minimal or mild progression also occur [3,4].
Structurally, nemaline bodies are extensions of Z-disks and are
comprised primarily of the Z-disk protein a-actinin [5,6] but also
contain myotilin [7] and sarcomeric a-actin [8]. Nemaline bodies
can occur in combination with cores (core-rod myopathy;
[3,9,10,11,12]), as a secondary feature in mitochondrial disorders
[13] and in patients with HIV [14]. In addition, nemaline bodies
can be induced experimentally [15] and sarcomeric rod-like
structures form in DMSO-treated muscle cultures [16,17].
Mutations in genes coding for six different proteins associated
with muscle thin filaments have been shown to cause nemaline
myopathy, namely slow muscle a-tropomyosin (TPM3) [18],
nebulin (NEB1) [19], skeletal muscle a-actin (ACTA1) [20],
troponin T1 (TNNT1) [21], slow muscle b-tropomyosin (TPM2)
[22] and muscle-specific cofilin (CFL2) [23]. Nemaline myopathy
with cores or core-like regions is caused by mutations in ryanodine
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domains-containing protein 13 (KBTBD13; [24]). Mutations in
NEB1 and ACTA1 are the commonest causes of nemaline
myopathy. Linkage analysis indicates that mutations in NEB1
account for at least 50% of all nemaline myopathy patients [25]
whereas mutations in ACTA1 have been shown to cause
approximately 25% of all nemaline myopathy, but 50% of the
severe presentations [4]. Mutations in the other known causative
genes probably contribute 5-10% of cases, with the remaining
causative genes/mutations not yet identified, e.g. [26].
There are currently .180 known ACTA1 mutations distributed
through all 6 coding exons of the gene [27] (http://www.waimr.
uwa.edu.au/research/lovd.html). These mutations not only pro-
duce nemaline myopathy but are also associated with additional
pathological features such as intranuclear rods, actin accumula-
tion, cores and fibre type disproportion [3,20,28,29]. Most ACTA1
mutations are missense, dominant de novo mutations, with the
majority of patients having a severe congenital myopathy
phenotype and not surviving to one year of age [27]. There is
some correlation between the location of the mutated residue and
the amino acid substitution (in the case of missense mutations) with
the disease phenotype and severity [30]. However, due to the small
number of patients with any specific mutation, the extreme disease
severity and paucity of muscle biopsy material, the possibilities for
investigating the pathobiology of ACTA1 mutations using patient
muscle are limited.
In order to overcome this difficulty we have investigated
transgenic mouse and tissue culture models of ACTA1 mutations.
We previously generated mouse models of ACTA1 nemaline
myopathy, with the D286G mutation and showed that the disease
severity correlated with the percentage of mutant protein [31].
Moreover, the vast majority of mice which expressed the ACTA1-
D286G protein at ,40% of wild-type presented with a severe
splayed leg and immobility phenotype in the early postnatal period
[31]. In tissue culture, transfecting C2C12 cells with mutant
ACTA1-EGFP proteins in general produces similar lesions to
those observed in patients’ biopsies, whereas transfection with WT
ACTA1-EGFP does not (e.g. [32,33]). In our hands C2C12 cells
transfected with an ACTA1 D286G-EGFP construct produce
cytoplasmic EGFP-positive aggregates in myoblasts and differen-
tiating myotubes that are not seen in the nuclei (unpublished data),
although it has been suggested that the D286G mutation does
produce intranuclear rods [34].
In order to allow specific visualisation of the mutant ACTA1
D286G protein in skeletal muscle of the resulting transgenic mice,
an enhanced green fluorescent protein (EGFP)-tag was included
in another ACTA1 D286G transgene construct. The trans-
genic C57BL/6J;CBA/Ca-Tg(ACTA1.D286G-EGFP) (abbrevi-
ated Tg(ACTA1)
D286G-EGFP) mice demonstrate structural abnor-
malities characteristic of nemaline myopathy, decreased activity
and muscle weakness. Thus this mouse model displays all the
hallmark features of nemaline myopathy, with the additional
benefit that the mutant ACTA1 protein can be tracked in the
presence of WT ACTA1 through the EGFP tag. In addition, the
transgenic mice show features of myofibrillar myopathy with
accumulations of granulofilamentous material by electron
microscopy and desmin accumulation by immunohistochemistry
and also large numbers of ringbinden and internal nuclei
suggestive of degeneration and regeneration of myofibres. This
mouse model thus provides a useful tool for the further study of
the pathogenesis of nemaline bodies, core-like areas and
ringbinden fibres and potential therapeutic interventions for
these pathologies and points to other possible patient cohorts to
screen for ACTA1 mutations.
The intensity of the ACTA1-D286G-EGFP signal varied
considerably not only between different muscle fibre types but
with age and serves as a cautionary note to researchers using
skeletal muscle promoter and enhancer constructs for expression
of transgenes.
Methods
Generation and screening of transgenic lines
All animal procedures were approved by the Animal Experi-
mentation Ethics Committee of The University of Western
Australia (RA03/100/918).
A transgenic mouse line expressing the ACTA1 protein
containing the D286G mutation, fused at the C terminus to the
coding sequence for EGFP was created using standard procedures
(Tinsley et al 1996). The line expressed the transgene under the
control of a cassette provided by E. Hardeman (University of New
South Wales, Sydney, New South Wales, Australia), containing a
2.2-kb fragment of the human skeletal muscle a-actin promoter
(HSA) [35] and the troponin-I slow upstream enhancer ([36] as
with our previous mouse models [31,37].
The transgenic expression construct was made as follows: The
human ACTA1 cDNA sequence (minus the stop codon) was
amplified from human skeletal muscle cDNA, reverse transcribed
from RNA extracted from control human skeletal muscle. The
D286G mutation was introduced by site directed mutagenesis
(Stratagene) and was confirmed by sequencing. Next, the
ACTA1(D286G) sequence was inserted into the pEGFP-N1
plasmid (Clontech) before subsequent excision of the entire
ACTA1(D286G) + EGFP sequence. A 17 amino acid linker
existed between ACTA1(D286G) and EGFP, derived from the
sequence of the pEGFP-N1 multiple cloning site.
Then, through a series of multiple sub-cloning steps, the ACTA1
(D286G) cDNA sequence and the EGFP cDNA sequence, the
157 bp human TnI slow enhancer, and the 2.2 kb fragment of the
HSA promoter, were inserted in the pcDNA3.1(+) plasmid
(Invitrogen) backbone. Subsequently, the 4.5 kb combined insert,
plus ,800 bp of the bovine growth hormone poly A tail from the
adjacent pcDNA3.1(+) backbone was excised as one DNA
fragment and later used for injection into CBA/Ca x C57BL/6J
mouse embryos by usual techniques to create the transgenic mouse
line C57BL/6J;CBA/Ca-Tg(ACTA1.D286G-EGFP), abbreviated to
Tg(ACTA1)
D286G-EGFP. Positive offspring were detected by PCR on
tail-tip DNA using primers designed against the HSA promoter
sequence.
Histology and immunohistochemistry (IHC)
Freshly excised skeletal muscles were frozen in optimum cutting
temperature (OCT) medium using liquid nitrogen cooled
isopentane. Gomori trichrome staining was performed on 8–
10 mm sections, cut on a Leica Jung CM cryocut 1800, according
to standard procedures used in routine diagnostics to detect the
presence of nemaline bodies [38].
For IHC, 10 mm sections were blocked for 1 hr in 1% bovine
serum albumin (BSA) and 10% fetal calf serum (FCS) in phosphate
buffered saline (PBS) at room temperature. Mouse IgG1
monoclonal antibodies against a-actinin (EA-53, diluted 1:10,
Sigma-Aldrich), MHCI (NCL-MHC1, diluted 1:10, Novocastra),
MHCIIA (SC-71, diluted 1:3, DSHB), desmin (D033, diluted 1:50,
Dako) and aB-crystallin (1B6.1-3G4, diluted 1:20, Abcam) were
conjugated to ZenonH AlexaFluorH (Invitrogen; either 350, 488 or
594), diluted in the FCS/BSA solution and incubated overnight at
4uC. After three 5-min washes in PBS, the sections were mounted
in Hydromount (National Diagnostics). The ZenonH technology
ACTA1-EGFP Congenital Myopathy Mouse
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antibodies on mouse tissue.
Mouse IgM monoclonal antibodies against MHCIIB (BF-F3,
diluted 1:10, DSHB) and MHCIIX (6H1, used neat, [39]) were
incubated on sections overnight at 4uC in the BSA solution. The
sections were washed three times for 5 min and incubated for 1 hr
with a goat anti-mouse IgM secondary antibody (diluted 1:1000;
Alexa FluorH 488, Invitrogen) followed by three more washes with
PBS. Rabbit polyclonal anti-myotilin antibody (diluted 1:100,
[40]) was incubated on sections overnight at 4uC in the BSA
solution, followed by three 5-min washes with PBS, and then a
1 hr incubation with a goat anti-rabbit secondary antibody
(diluted 1:1000; Alexa FluorH 555, Invitrogen) followed by three
5-min washes with PBS. Appropriate isotype (mouse IgG1, IgM or
rabbit IgG), positive and negative controls were used for each
experiment. Sections were visualised using an inverted fluorescent
microscope (Olympus model IX-71) and digital camera (model
DP-71, Olympus) or confocal microscope (model MRC1000/
1024, Biorad Laboratories Pty Ltd).
Fibre typing and morphometry
MHC fibre-type proportions and morphometry were deter-
mined for EDL and SOL muscles from 1 and 4-month old mice as
described previously [37,41].
Electron microscopy (EM)
Muscles were removed and immediately cut into very thin strips
before immersion in 2.5% glutaraldehyde in 1 M cacodylate
buffer, pH 7.4. Samples were post-fixed with 2% osmium
tetroxide for 30 min, dehydrated through an ascending series of
ethanols, embedded in Spurr’s epoxy resin and cured for at least 3
days at 70uC. Ultrathin sections (70 nm) were cut with a LKB
8800 ultramicrotome and grids viewed and photographed with a
JEOL 2100 transmission EM and 11 mega-pixel Orius digital
camera.
Skinned fibre analysis
Analysis of the contractility of mechanically-skinned EDL fibres
from 6-month old Tg(ACTA1)
D286G-EGFP and WT mice was
performed as previously described [31,37].
Whole muscle contractility
The contractile properties of excised EDL and SOL muscles
from 1-month old male mice were examined using an Intact
Muscle Test System (Aurora Scientific Inc.) as previously
described [31,37]. Twitch force (force developed in response to
a single action potential) and tetanic force response elicited in
response to trains of stimulation pulses at different frequencies (10,
20, 40, 60, 80, 100 and 120 Hz) were recorded. A 3 min interval
was allowed between trains of stimuli, to prevent fatigue. The
tetanic responses were normalised to percentage of maximal force
to examine the specific effects of stimulation frequency on force
production.
Specific force (N/cm
2) was determined using the method of
[42]. At completion of functional testing, muscles were trimmed,
blotted and weighed to determine muscle mass (mm). Muscle
cross–sectional area (CSA) was determined by dividing mm by the
product of fibre length (Lf) and the density of mammalian skeletal
muscle [1.06 mg/mm
3; [43]]. Lf was calculated by multiplying the
optimal muscle length (Lo) by a previously determined EDL Lf-to-
Lo ratio of 0.45 and SOL Lf-to-Lo ratio of 0.71 [42]. The
maximum isometric specific forces (sPo) and specific twitch forces
(sPt) were then determined using the formula described in [44].
Running wheel experiments
One-month old WT and Tg(ACTA1)
D286G-EGFP mice were
housed singularly in cages containing a standard mouse running
wheel connected to a speedometer which recorded distance
travelled, time spent moving, average and maximum speeds.
Activity was monitored every 24 hours over a 7-day period and
the average distance travelled per day calculated.
Statistics
GraphPad Prism 4 was used to conduct two-tailed t tests with
Welch’s correction for all the statistical analyses, except for the
force-frequency datasets. Multivariate analyses of variance were
conducted using Statistica (StatSoft Pacific Pty Ltd) with main
effects of genotype and repeated measures of frequency. When the
ANOVA indicated significant main effects and interaction,
individual means were compared with a Student–Newman–Keuls
post hoc test. All data are presented as the mean 6 standard error
of the mean.
Results
Tg(ACTA1)
D286G-EGFP mice developed rod-like bodies
Gomori trichrome staining revealed intense red-staining
structures similar to nemaline bodies as seen in nemaline
myopathy patients and serial sections showed that EGFP-positive
accumulations correlated with the location of these in the EDL,
SOL, gastrocnemius and quadriceps muscles (Figure 1.A). Quad-
riceps muscle from 4-month old mice expressing the AC-
TA1(D286G)-EGFP fusion protein contained numerous EGFP-
positive accumulations and rod-like structures (Figures 1.B and C).
The majority of these aggregates also co-stained with antibodies to
the Z-disk proteins a-actinin (Figure 1.B) and myotilin (Figure 1.C),
both proteins shown to be present in nemaline bodies. At the
ultrastructural level, electron-dense nemaline bodies were ob-
served in various muscles from Tg(ACTA1)
D286G-EGFP mice
(Figure 1.D) suggesting that the red-staining structures visualised
by Gomori trichrome were indeed nemaline bodies. Thickened Z-
disks and extensions of the Z-disks were also observed in
Tg(ACTA1)
D286G-EGFP muscle by EM (Figure 1.D).
Muscle physiology
To investigate the functional consequences of the mutant
skeletal muscle a-actin and associated structural abnormalities, the
contractile properties of isolated EDL and SOL muscles of 1-
month old WT and Tg(ACTA1)
D286G-EGFP mice were examined.
Maximal specific force was significantly decreased in both EDL
(,79% of WT; p=0.026) and SOL muscles of the Tg(AC-
TA1)
D286G-EGFP mice, with the SOL most greatly affected (,42%
of WT; p,0.0001; Figure 2.A). In addition, the force-frequency
relationship of Tg(ACTA1)
D286G-EGFP SOL muscles exhibited a
marked shift to the right compared to WT (Figure 2.B), indicating
that a greater stimulation frequency was required in Tg(AC-
TA1)
D286G-EGFP SOL muscles to produce a similar amount of force
to WT. Conversely, the force-frequency relationship of Tg(AC-
TA1)
D286G-EGFP EDL muscle displayed a small, but significant shift
to the left compared to WT EDL muscles (Figures 2.C). The peak
specific twitch force (sPt) was significantly diminished in Tg(AC-
TA1)
D286G-EGFP SOL muscles compared to WT, but there was no
significant difference in sPt between Tg(ACTA1)
D286G-EGF and WT
EDL muscles (Table 1). No significant difference in the
contraction or relaxation times of the twitch responses was found
in the EDL or SOL muscles of Tg(ACTA1)
D286G-EGFP and WT
mice (Table 1). These results indicate that the actin mutation in
Tg(ACTA1)
D286G-EGFP mice significantly alters skeletal muscle
ACTA1-EGFP Congenital Myopathy Mouse
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the predominantly slow twitch SOL muscle.
Behavioural analysis
Voluntary running wheel activity of 1-month old Tg(AC-
TA1)
D286G-EGFP mice was significantly reduced over a seven-day
period. The average distance travelled per day by the Tg(AC-
TA1)
D286G-EGFP mice was ,30% less than that of WT mice
(p=0.02; Figure 2.D). However average and maximum speeds
were similar for Tg(ACTA1)
D286G-EGFP and WT mice (Figures 2.E
and F).
Transgene protein levels varied in different muscles at
different ages and in different fibre types
The intensity of the EGFP-signal (reflective of the amount of
mutant skeletal muscle a-actin protein present), and the extent of
structural abnormalities varied considerably with age and across
different muscles (Figs 3 and 4). During the early PN period (PN
d3 and d5) all limb muscle fibres examined showed similar levels of
the EGFP fusion protein (Figure 3.A). However, by PN d7 there
was variation in the EGFP signal intensity in different muscle
fibres, with this variation becoming more pronounced with PN
development, such that at PN d25 there were clearly two
populations of fibres: high and low EGFP-expressors. At 1 month
of age, levels of the transgenic protein in the SOL were greater in
MHCI and MHCI/IIA hybrid fibres, whereas by 4 months of age
levels were was negligible in MHCIIA fibres and low in MHCI
fibres and considerably less than in EDL MHCIIB and IIX fibres
(Figure 3.B). By 4 months of age in the EDL, the ACTA1(D286G)-
EGFP protein became confined to predominantly MHCIIB and
MHCIIX fibres and was absent from MHCIIA fibres (Figure 3.B).
This fibre-type dependent expression of the transgene is likely to
be at least partially responsible for the altered EGFP signal
intensities observed between different muscles and at different ages
(Figure 4), with levels of the ACTA1(D286G)-EGFP protein high
in all muscles at the younger timepoint of 1 month compared to 4
months. The diaphragm of Tg(ACTA1)
D286G-EGFP expressed very
little EGFP at all ages examined. Interestingly, mutant protein was
never detected in the intrafusal fibres within the muscle spindles
(Figure 1.A).
C o u p l e dw i t ht h e s ea l t e r a t i o n si nt h el e v e lo ft h eA C -
TA1(D286G)-EGFP a-actin with fibre type and age was a shift
Figure 1. Nemaline bodies were a prominent feature of Tg(ACTA1)
D286G-EGFP muscle. (A) Gomori trichrome staining revealed that nemaline
bodies (see insert) were a prominent feature of Tg(ACTA1)
D286G-EGFP muscles, especially at 1 month of age. Serial sections showed that the location of
these nemaline bodies corresponded with regions of intense EGFP aggregates. Note also the presence of internal nuclei, the large variation in fibre
size in muscle of Tg(ACTA1)
D286G-EGFP mice and the absence of EGFP signal in spindle fibres (arrows). These first two characteristics were not observed
in WT muscle (Figure 1.E: WT EDL muscle stained with Gomori trichrome). ACTA1(D286G)-EGFP a-actin was incorporated into the sarcomeres as seen
by the striated EGFP signal but also formed intensely fluorescing aggregates in quadriceps muscles (B, C). The EGFP-positive aggregates labeled with
antibodies to the Z-disk proteins a-actinin (B) and myotilin (C). (D) Electron-dense nemaline bodies were observed as extensions of the Z-disk. These
were most frequently observed in the SOL muscle of 1-month old and the EDL and gastrocnemius muscles of 4-month or older Tg(ACTA1)
D286G-EGFP
mice. Scale bars = 50 mm (A, E), 25 mm (B, C) and 2 mm (D).
doi:10.1371/journal.pone.0028699.g001
ACTA1-EGFP Congenital Myopathy Mouse
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muscles in the transgenic mice compared to WT mice (Figure 5).
In the Tg(ACTA1)
D286G-EGFP EDL muscle at 1 month of age
there was a significant reduction in the proportion of pure fibres
(p=0.024) with a concurrent increase in the proportion of
hybrid fibres expressing more than one MHC isoform
(Figure 5.A, p=0.028). All fibre types were smaller in
Tg(ACTA1)
D286G-EGFP EDL than in WT muscle, however the
fibre size difference was only significant for pure MHCIIB
(p,0.001) and hybrid MHCIIB/IIX fibres (p,0.05, Figure 5.B).
At 4 months of age no differences in the EDL fibre type
proportions were observed compared to WT muscle and only
p u r eM H C I I Bf i b r e s( t h em u s c l ef i b r e sw i t ht h eh i g h e s t
expression of the transgene) were significantly smaller
(p,0.01). At 1 month, Tg(ACTA1)
D286G-EGFP SOL muscle
contained a reduced proportion of MHCIIA (p=0.018)a n d
an increased contribution of MHCI/IIA hybrid fibres
(Figure 5.A, p=0.002), with all fibre types significantly smaller
than WT fibres (Figure 5.B). The decreased contribution of
MHCIIA fibres observed in the 1-month old SOL muscle of
Figure 2. Tg(ACTA1)
D286G-EGFP mice were weak and less active at 1 month of age than WT control mice. (A) sPo was significantly lower in
EDL (n=9, p=0.026) and SOL muscles (n=10, p,0.0001)o fTg(ACTA1)
D286G-EGFP mice compared to that of WT muscle (EDL: n=11, SOL: n=8). (B) In
the SOL muscles from Tg(ACTA1)
D286G-EGFP mice, the force–frequency relationship displayed a significant shift to the right compared to WT. (C) The
force-frequency relationship was shifted to the left in the Tg(ACTA1)
D286G-EGFP EDL muscles compared to WT EDL (NOTE: for some data points the SEM
bars are too small to be seen). (D) One-month old Tg(ACTA1)
D286G-EGFP mice (n=8) used voluntary running wheels less than WT mice (n=9), and
traveled 30% less distance on average, per day. (E) Average and (F) maximum speeds were not different between Tg(ACTA1)
D286G-EGFP and WT mice.
*p,0.05, **p=0.005, ***p,0. 001.
doi:10.1371/journal.pone.0028699.g002
ACTA1-EGFP Congenital Myopathy Mouse
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28699Tg(ACTA1)
D286G-EGFP mice persisted at 4 months of age
(p,0.001) and there was also a significant increase in the
percentage of pure MHCI fibres (p=0.002).
Tg(ACTA1)
D286G-EGFP muscles demonstrate other
pathologies: internal nuclei, core-like areas,
granulofilamentous electron dense inclusions and
ringbinden
In addition to the presence of nemaline bodies, EM revealed
that a number of different pathological features were present in
skeletal muscle of the Tg(ACTA1)
D286G-EGFP mice, including
internal nuclei (Figure 6) core-like regions, cores containing rods,
granulofilamentous electron-dense inclusions (Figure 7) and ring-
binden (Figure 8).
At PN d14 the percentage of internally nucleated fibres in the
EDL and SOL was similar for WT and Tg(ACTA1)
D286G-EGFP
muscle at ,1%. However, the number of internally-nucleated
fibres was elevated in both EDL and SOL muscles of
Tg(ACTA1)
D286G-EGFP mice compared to WT mice at 1 and 4
months of age with up to ,15% of muscle fibres demonstrating
internal nuclei (Figures 6.A and B). Internal nuclei were also a
prominent feature of the quadriceps and gastrocnemius of
Tg(ACTA1)
D286G-EGFP mice older than 1 month and were present
in fibres of all MHC types (data not shown).
Core-like regions, cores containing rods and granulofilamentous
electron-dense inclusions were most common in the SOL muscle
of 1-month old Tg(ACTA1)
D286G-EGFP mice (Figures 7.A-E). As
granulofilamentous inclusions are frequently observed in myofi-
Table 1. Contractile properties of twitch responses elicited in
EDL and SOL muscles from Tg(ACTA1)
D286G-EGFP and WT mice.
Table 1: Contractile properties of twitch responses
WT Tg(ACTA1)
D286G-EGFP p-value
sPt (N/cm
2)
EDL 4.2860.31 (12) 3.4360.35 (9) 0.085
SOL 2.1360.14 (8) 0.41160.14 (9) ,0.0001
TTP (ms)
EDL 22.360.5 23.160.5 0.255
SOL 41.961.2 40.162.4 0.522
K RT (ms)
EDL 29.162.1 29.662.3 0.889
SOL 55.864.8 50.266.6 0.509
Data are presented as mean 6 SEM, values in parenthesis represents the n of
isolated muscles used per group.
doi:10.1371/journal.pone.0028699.t001
Figure 3. Expression of the ACTA1(D288G)-EGFP fusion a-actin protein changes with MHC fibre type and was associated with an
increased contribution of MHC hybrid fibres. (A) A time-course of EGFP-expression in the gastrocnemius muscle indicated that during the early
PN period all fibres expressed similar levels of ACTA1(D288G)-EGFP. By PN d7 expression was slightly reduced and by PN d25 a proportion of the
fibres expressed comparatively low levels of ACTA1(D288G)-EGFP. (B) IHC of serial sections of SOL and EDL muscles from 1- and 4-month old
Tg(ACTA1)
D286G-EGFP mice revealed that in the SOL, the fibres expressing the most ACTA1(D288G)-EGFP were MHCI and MHCI/IIA hybrids (1 month) or
pure MHCI fibres (4 months). In the EDL, the EGFP signal was most intense in the MHCIIB fibres for both timepoints. By 4 months of age in the EDL,
MHCIIA fibres were essentially negative for EGFP by comparison to MHCIIB and MHCIIX fibres. Scale bar = 50 mm. Note the EGFP images were not all
taken at the same exposure times for gastrocnemius, EDL and SOL muscles but were instead taken at the settings required to achieve sufficient EGFP
signal to facilitate visualisation of the fibres.
doi:10.1371/journal.pone.0028699.g003
ACTA1-EGFP Congenital Myopathy Mouse
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proteins was examined. Muscle samples from 1-month old
Tg(ACTA1)
D286G-EGFP mice were demonstrated to contain accu-
mulations of desmin and aB-crystallin that were not seen in WT
muscle (Figures 7.F and G).
The presence of ringbinden was a prominent feature of muscle
from adult Tg(ACTA1)
D286G-EGFP mice. By light microscopy, these
fibres were best observed with Gomori trichrome staining and a-
actinin immunostaining (Figures 8.A and 8.B). They were
frequently observed in the EDL, gastrocnemius and quadriceps
muscles of adult Tg(ACTA1)
D286G-EGFP mice. In the EDL muscle of
4 month old Tg(ACTA1)
D286G-EGFP mice approximately 9% of
fibres were ringbinden (n=5). By EM these fibres contained
aggregates of 2 to 7 myofibrils arranged concentrically around the
bulk of longitudinally orientated myofibrils (Figure 8.B). Fibre
typing by IHC for specific MHC isoforms, performed on serial
sections of gastrocnemius muscle, revealed that the ringbinden
were exclusively MHCIIB fibres, though not all MHCIIB fibres
were ringbinden (Figure 8.C). Ringbinden were never observed in
SOL muscle, which comprises only MHCI and MHCIIA fibres, or
in the other muscles, EDL, gastrocnemius and quadriceps at the
earlier, 1 month, timepoint.
Discussion
Tg(ACTA1)
D286G-EGFP mice model nemaline myopathy
Gomori trichrome staining of serial sections revealed the
presence of nemaline bodies within different muscles of Tg(AC-
TA1)
D286G-EGFP mice. These nemaline bodies correlated with
strong EGFP signals indicating that the nemaline bodies likely
contained the ACTA1(D286G)-EGFP protein (Figure 1.A). Skel-
etal muscle of Tg(ACTA1)
D286G-EGFP mice contained numerous
aggregates of the mutant fusion protein that co-labelled with the Z-
disk proteins a-actinin and myotilin (Figures 1.B and C) - which
both label nemaline bodies in patient biopsies [5,6,7]. At the
ultrastuctural level, numerous electron-dense nemaline bodies
were observed as extensions of the Z-disk in the SOL, EDL and
gastrocnemius muscles of different aged Tg(ACTA1)
D286G-EGFP
mice (Figure 1.D). Thus, the Tg(ACTA1)
D286G-EGFP mouse model
displays the pathological hallmarks of nemaline myopathy.
Contemporaneous to the peak occurrence of structural lesions at
1 month of age, 1-month old Tg(ACTA1)
D286G-EGFP mice also
exhibited reduced voluntary activity on running wheels
(Figure 2.D) and isolated muscles were significantly weaker than
those of WT mice. The muscle weakness was more pronounced in
the muscle with the most severe structural abnormalities, i.e. 1
month SOL muscle (Figures 2.A). The age-dependent features
correlated with the levels of the ACTA1(D286G)-EGFP protein
present over time. Taken together, the Tg(ACTA1)
D286G-EGFP
mouse line is an excellent model of both the characteristic
pathological lesions and the muscle weakness of nemaline
myopathy, similarly to our Tg(ACTA1)
D286G models [31].
A previous study showed that skeletal muscles from a mouse
expressing EGFP alone (driven by the b-actin promoter) are
fluorescent green and have ‘‘very high levels of GFP expression’’,
however they do not report any kinds of skeletal muscle pathology
due to this EGFP expression, and there was no mention of any
rod-like bodies. Thus the presence of EGFP rod-like bodies in our
model is unlikely to be due simply to high levels of the
ACTA1(D286G)-EGFP protein [46].
Transgenic protein levels and structural lesions varied in
different muscles, muscle fibre types and ages
Levels of the mutant protein varied between different skeletal
muscles and at different ages, as highlighted in Figures 1, 3 and 4.
During the early PN period the mutant protein was present at
similar levels in all myofibres (until approximately PN d7) and then
diminished in some fibre types more than others (Figure 3.A). The
fibres that were brightest for EGFP in the 1- and 4-month old
EDL muscle biopsies were MHCIIB-positive (Figure 3.B), with the
mutant protein remained at high levels in MHCIIB fibres at 4
months of age and in MHCIIX fibres only at lower levels.
Figure 4. The EGFP signal intensity varied between muscles
and diminishes with age. The EGFP signal imaged under the same
exposure settings clearly demonstrated that the amount of mutant
skeletal muscle a-actin-EGFP varied between different muscles, with
intense EGFP aggregates most frequent in the EDL, gastrocnemius and
SOL muscles at 1 month of age. By 4 months of age the intensity of the
EGFP signal was reduced in all muscles compared to the 1-month time
point. This was most noticeable in the SOL muscle. The diaphragm was
largely EGFP-negative at both time-points. Scale bar = 50 mm.
doi:10.1371/journal.pone.0028699.g004
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a-actin (HSA) promoter produces a fibre-type dependent expres-
sion of the transgene, with greatest expression in MHCIIB fibres
[47,48]. Preferential effects of transgenes in fast glycolytic fibres
has previously been reported for other muscle gene promoters,
including the muscle creatine kinase promoter [49] and the
myosin light chain promoter [50]. Our current study using the
easily-visualised EGFP-tagged skeletal muscle a-actin has high-
lighted the large variations and transient nature of transgene
expression under the control of the HSA promoter and TnI(slow)
enhancer in different muscle fibre types and the potential pitfalls of
interpretation of mouse models generated using these promoter
Figure 5. Fibre-type proportions and fibre size were significantly different in Tg(ACTA1)
D286G-EGFP muscle. (A) At 1 month of age,
Tg(ACTA1)
D286G-EGFP SOL muscle (n=8) contained significantly less MHCIIA fibres and a concurrent increase in the percentage of MHCI/IIA hybrid fibres
than in 1-month old WT SOL muscle (n=9). This change persisted at 4 months, and in addition the Tg(ACTA1)
D286G-EGFP SOL (n=5) also contained a
higher percentage of MHCI fibres than WT SOL (n=5). At 1 month of age a significant increase in the percentage of hybrid fibres was observed in
Tg(ACTA1)
D286G-EGFP EDL muscle (n=7) compared to WT EDL (n=10). By 4 months of age the contribution of hybrid versus pure fibres was not
significantly different for WT (n=6) and Tg(ACTA1)
D286G-EGFP (n=5) EDL muscle. (B) Morphometry of EDL and SOL muscle fibres at 1 and 4 months of
age revealed that there is a trend towards all Tg(ACTA1)
D286G-EGFP fibres being smaller than WT. This feature was more striking at the 1-month time-
point for both the EDL and SOL fibres. *p,0.05,* * p,0.01, ***p,0.001 compared to WT.
doi:10.1371/journal.pone.0028699.g005
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in the Tg(ACTA1)
D286G+/+ mouse model lacking the EGFP tag [31]
where further (unpublished) studies have shown that the
percentage of mutant protein, as determined by mass spectrom-
etry, was similar in 1- and 4-month old gastrocnemius muscles but
was reduced by ,80% in 4-month old SOL muscles compared to
1-month old SOL. Recently, Tai et al. 2011, identified the
modulatory region 1 in intron 1 of the muscle creatine kinase gene
as enhancing MCK promoter construct expression in slow, type I
and fast type IIA fibres [51]. Similar regions must exist for the
other muscle genes but have not yet been precisely identified [35].
Pathophysiology – disease mechanisms
Although differences in the extent of the pathological lesions
within muscle from the Tg(ACTA1)
D286G-EGFP mice might be
presumed to reflect the altered physical demands and stresses
placed on each, the degree of structural abnormalities does not
appear to correlate with muscle use since the diaphragm is
relatively unaffected even at PN d14 (data not shown, Figure 4). A
similar finding was reported for the Met9Arg TPM3 nemaline
myopathy transgenic mouse [48]. In the Tg(ACTA1)
D286G-EGFP
mice, the SOL muscle comprises a similar MHC isoform
composition to the diaphragm, thus a high percentage of MHCIIA
fibres cannot alone account for the relative absence of
ACTA1(D286G)-EGFP a-actin protein and EGFP-aggregates in
the diaphragm. This finding possibly indicates that physiotherapy,
exercise and related activities may not induce muscle damage in
certain congenital myopathy patients. A study of the Met9Arg
TPM3 transgenic congenital myopathy mouse revealed that
disuse-induced muscle weakness and nemaline body formation
could be mitigated with exercise [52]. At the clinical level there is a
growing body of anecdotal evidence to suggest that exercise may
be beneficial for patients with congenital myopathies, including
ACTA1 congenital myopathies [53,54].
In this study, the EDL and SOL muscles from
Tg(ACTA1)
D286G-EGFP mice were significantly weaker than WT at
1 month of age. These findings are likely because of decreased
numbers of functional sarcomeres, due to the presence of non-
contractile areas such as nemaline bodies and core-like regions.
The 1 month SOL muscles had a greater percentage reduction in
maximum force compared to EDL muscles, consistent with the
greater incidence of (non-contractile) core-like regions and
granulofilamentous electron dense inclusions in SOL fibres
compared to other Tg(ACTA1)
D286G-EGFP muscles (Figure 7.A).
In 1-month old Tg(ACTA1)
D286G-EGFP mice the percentage of
internally nucleated fibres was increased 15- and 9-fold compared
to WT mice in EDL and soleus muscles, respectively. This
difference persisted at 4 months of age (Figures 6.A and B). Despite
the fact that Met9Arg TPM3 nemaline myopathy mice are
reported to have delayed maturation on the basis of perturbed
muscle fibre-type proportions, internally-nucleated fibres have not
been observed [48,52,55]. Internal nuclei are associated with
Figure 6. Internally-nucleated fibres were a persistent feature of skeletal muscle from Tg(ACTA1)
D286G-EGFP mice post-weaning. (A)
Representative images taken of Hoechst-labeled EDL and SOL muscles from PN d14, 1 and 4-month old Tg(ACTA1)
D286G-EGFP mice showed the
occurrence of internally-nucleated fibres in post-weaned Tg(ACTA1)
D286G-EGFP mice. A representative image of a WT EDL muscle labelled with
phalloidin-FITC and Hoechst is also shown. (B) The percentage of internally-nucleated fibres in whole EDL (1m, 4m WT: n=7, n=6; Tg: n=10, n=5)
and SOL (1m, 4m WT: n=9, n=5; Tg: n=8, n=5) muscles was determined for WT and Tg(ACTA1)
D286G-EGFP mice, with a significant increase seen in
Tg(ACTA1)
D286G-EGFP muscle. However there was no significant difference in the number of internally nucleated fibres in EDL and SOL muscles (WT:
n=7, Tg: n=4)o fTg(ACTA1)
D286G-EGFP mice at PN d14. *p,0.05 compared to WT, **p,0.01 compared to WT.
doi:10.1371/journal.pone.0028699.g006
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such are a characteristic feature of dystrophic muscle. They are
not however, usually a feature of nemaline myopathy; therefore it
is of interest that internal nuclei were present in a Tg(AC-
TA1)
D286G-EGFP muscle. It is well known that the mdx mouse (model
of Duchenne muscular dystrophy) undergoes a period of extensive
degeneration and regeneration coincidental with weaning (, PN
d21), which is thought to be a result of increased motor activity
[57]. Thus the observed abundance of internally nucleated fibres
at 1 month of age (but not PN d14), in the Tg(ACTA1)
D286G-EGFP
mice may be due to a similar trigger to that in the mdx mouse, and
this feature persisted at 4 months of age.
It has been demonstrated by in vitro studies that certain ACTA1
mutations induce cell death [34,58,59]. The mutations studied in
Wallefeld et al. (2006) affect the normal termination codon, and as
a result part of the normal 39-UTR is translated, resulting in a
larger actin protein. The clinical phenotype of all patients
identified to date with such mutations is severe, with an atypical
markedly dystrophic phenotype consisting of loss of muscle fibres
and fibrosis seen on muscle biopsy [58]. The actin protein
Figure 7. SOL muscle of 1-month old Tg(ACTA1)
D286G-EGFP mice displayed, in addition to nemaline bodies, a number of alterations at
the ultrastructural level that are found in rod-core and myofibrillar myopathies. (A) Aggregates of sarcoplasmic reticulum profiles
punctuated by scattered autophagosomes, mitochondria and intermediate filaments. (B) An intermyofibrillar aggregate of fine filaments and electron
dense rods of varying dimensions. (C) A collection of anastomosing, irregular electron dense rods into which fine filaments are inserting. The electron
dense rods have a faintly fibrillar substructure. (D) Fibrillogranular electron dense material accumulating along the plane of the Z-bands. Note that
the Z-bands are fragmented and there is disorganisation of the sarcomeric myofilaments. (E) Transverse view of electron dense fibrillogranular
material. Labelling of SOL muscle sections from Tg(ACTA1)
D286G-EGFP mice revealed altered localisation and expression levels of desmin and aB-
crystallin (G) compared to that seen for WT muscle (F). Desmin expression was more diffuse throughout the muscle fibres in Tg(ACTA1)
D286G-EGFP
muscle compared to WT muscle. Fibres containing intense EGFP-positive aggregates also showed elevated levels of aB-crystallin compared to
neighbouring fibres. Scale bars = 2 mm (A-E), 20 mm (F–G).
doi:10.1371/journal.pone.0028699.g007
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having the EGFP C-terminal tag increasing the size of the actin
protein. Akin to the human patients with mutations of their
ACTA1 stop codon, the Tg(ACTA1)
D286G-EGFP mice have relatively
severe muscle pathologies despite low levels of mutant protein in
their muscle fibres.
Fibre type composition and fibre sizes were altered in
Tg(ACTA1)
D286G-EGFP mice
Coupled to the alterations in the fibre-type specific expression
of the transgene with development was an alteration in the fibre
type proportions in Tg(ACTA1)
D286G-EGFP muscle compared to
WT muscle (Figure 5). In the Tg(ACTA1)
D286G-EGFP EDL muscle
at 1 month of age a significant reduction in the proportion of
pure fibres was observed, with a concurrent increase in the
proportion of hybrid fibres and a decrease in the fibre diameter of
all fibres. Conversely by 4 months of age no significant differences
in fibre type proportions in EDL were detected compared to WT
muscle. At 1 month of age Tg(ACTA1)
D286G-EGFP SOL muscles
contained a reduced proportion of pure MHCIIA and an
increased contribution of MHCI/IIA hybrid fibres, with all fibre
types being significantly smaller than those of WT mice. The
decreased contribution of MHCIIA fibres observed in the 1-
month old SOL muscle of Tg(ACTA1)
D286G-EGFP mice persisted at
4 months of age, however there was also a significant increase in
the percentage of pure MHCI fibres. This indicates that the
elevated number of MHCI/IIA hybrid fibres observed at 1
month of age had perhaps with time converted into pure MHCI
fibres in the Tg(ACTA1)
D286G-EGFP SOL muscle. Thus, the
presence of an increased proportion of hybrid fibres in
Tg(ACTA1)
D286G-EGFP muscle at 1 month of age, likely reflects
muscle degeneration/regeneration and is consistent with the
occurrence of elevated numbers of internally-nucleated fibres
post-weaning in the Tg(ACTA1)
D286G-EGFP muscle (Figure 6).
Structural lesions other than nemaline bodies
A number of pathological features in addition to the classical
nemaline bodies were observed in Tg(ACTA1)
D286G-EGFP muscle by
EM, including core-like regions and granulofilamentous electron dense
inclusions (Figure 7.A). These features were most frequently observed
in the SOL muscle of 1-month old Tg(ACTA1)
D286G-EGFP mice. To
further examine the nature of these abnormalities, IHC was performed
for proteins that have been shown to comprise core-like regions and
osmiophilic inclusions. Antibodies to desmin and aB-crystallin
demonstrated abnormal staining in muscle from 1-month old
Tg(ACTA1)
D286G-EGFP mice (Figures 7.B and C). The desmin staining
pattern was more diffuse in the Tg(ACTA1)
D286G-EGFP muscle and
bright desmin-positive regions that were devoid of ACTA1(D286G)-
EGFP a-actin were observed. aB-crystallin staining was elevated in
Tg(ACTA1)
D286G-EGFP fibres that showed intense ACTA1(D286G)-
EGFP staining. These ultrastructural abnormalities and abnormal
desmin and aB-crystallin staining are the hallmarks of myofibrillar
myopathy (MFM). Slightly abnormal desmin and aB-crystallin staining
was also previously observed in Tg(ACTA1)
D286G fibres, but evidence of
Figure 8. Ringbinden fibres were a prominent feature of skeletal muscle from adult Tg(ACTA1)
D286G-EGFP mice. (A) Confocal imaging of
EDL muscle from a 4-month old Tg(ACTA1)
D286G-EGFP mouse showed the presence of numerous ringbinden fibres (arrows) that were best seen when
labelled with an antibody to a–actinin. (B) Ringbinden fibres were most frequent in EDL and gastrocnemius muscles of adult Tg(ACTA1)
D286G-EGFP mice
($ 4-months old) and were prominent by Gomori trichrome and toluidine blue staining (arrows). At the ultrastructural level, ringbinden fibres
consisted of 2 to 7 peripheral myofibrils arranged concentrically around the central myofibres. (C) Fibre-typing of gastrocnemius muscle using DAB of
consecutive sections, revealed that the ringbinden fibres were exclusively MHCIIB fibres.
doi:10.1371/journal.pone.0028699.g008
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diaphragm from a patient with this mutation were stated to contain
bright eosinophilic inclusions which is not the usual staining of
nemaline bodies and is more indicative of MFM, but the biopsy and
autopsy material are no longer available for study (Alan Beggs and
Caroline Sewry, personal communication). This finding suggests that
patients with MFM of unknown genetic origin should perhaps be
screened for ACTA1 mutations. Such a strategy might also be suggested
from the finding that abnormalities of actin localisation are seen in the
muscle fibres of MFM patients [60].
Ringbinden are a prevalent feature of Tg(ACTA1)
D286G-
EGFP muscle
Ringbinden are a frequent feature of muscular dystrophies and
myopathies [61], as well as being prevalent in muscles which do
not attach from bone to bone (e.g. the diaphragm and extraocular
muscle [62]). Studies of regenerating and/or tenotomised muscle
[63,64] or muscle prone to myotendinous junction disruption [65]
have shown that ringbinden fibres can be experimentally induced.
The presence of ringbinden in Tg(ACTA1)
D286G-EGFP EDL,
gastrocnemius and quadriceps muscles at 4 months of age
(Figure 8), but not 1 month of age, may be reflective of an
abnormal repair process or a protective mechanism. In our
previous study of Tg(ACTA1)
D286G mice, expressing the same
mutated actin (D286G) as in the present study but lacking the C-
terminal EGFP tag, we also only observed ringbinden in type IIB
fibres of 4-month or older Tg(ACTA1)
D286G mice. Ringbinden
were not present in muscle of Tg(ACTA1)
D286G. Acta1
+/- pups
despite the disease severity and greater percentage of mutant
protein [31]. This is in keeping with the hypothesis that ringbinden
may arise due to an abnormal repair process over time rather than
due to the extent of muscle weakness or structural lesions [65].
In conclusion, the Tg(ACTA1)
D286G-EGFP mouse models nema-
line myopathy both in terms of muscle weakness and abnormal
morphology, and as such could be used to understand better the
pathobiology of the disease as well as serve as a useful animal
model in which to test possible therapies. Due to the EGFP tag,
this model is uniquely placed to specifically track the location of
the mutant ACTA1 protein in the presence of WT ACTA1. The
altering expression of both the ACTA1-D286G-EGFP and
ACTA1-D286G transgenes provides a cautionary tale to those
researchers using similar expression constructs to mediate
expression of transgenes. Furthermore, the various structural
lesions (core-like regions, osmiophilic inclusions and ringbinden
fibres), observed in these mouse models, support the proposal that
the various pathological features observed in biopsies from ACTA1
patients represent a continuum of disease features rather than
discrete pathological entities. Finally, patients with large numbers
of ringbinden-containing fibres and/or myofibrillar myopathy
pathologies and no molecular explanation of their diseases should
probably be tested for ACTA1 mutations.
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